Prime Therapeutics Introduces IntegratedRx™ – Oncology

Prime Therapeutics, a leading pharmacy benefit manager (PBM) collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans serves more than 33 million members, recently introduced IntegratedRx™ – Oncology.

This new clinically integrated program streamlines the treatment pathway for members who are fighting cancer so they can now receive their oral oncolytic and companion medications in the clinical setting directly from their oncologist’s clinic or affiliated hospital pharmacy.

The IntegratedRx – Oncology program represents Prime’s channel independent approach of identifying solutions that drive the best financial and quality outcomes for Blue Plans and members. It makes Prime the only large PBM that doesn’t prioritize a central fill specialty pharmacy as the primary model to receive their oral oncolytic medications.

The nationwide rollout of IntegratedRx – Oncology builds on a successful pilot program with McKesson Health Mart Atlas, the largest pharmacy services administrative organization (PSAO) in the U.S., conducted in Florida, Minnesota and the Pacific Northwest earlier this year.

Prime is also collaborating with other national health care companies to operationalize and ensure success of the program, including AmerisourceBergen and Shields Health Solutions. As a leading distributor of specialty pharmaceuticals, AmerisourceBergen is now offering IntegratedRx to physician practice and health systems customers.

Prime also announced that it will prefer for its IntegratedRx™  – Oncology program the new specialized accreditation from NCODA, the leading nonprofit association for the patient-centered medically integrated oncology community. This first-in-market accreditation – which aligns with Prime’s essential accreditation criteria – is a component of required credentialing for IntegratedRx – Oncology.

NCODA recently announced its new Center of Excellence (CoE) Medically Integrated Pharmacy (MIP) Accreditation Program. The program, based on compliance with the ASCO/NCODA Patient-Centered Standards for Medically Integrated Dispensing, focuses on enhanced patient care and quality of services.  


Takeaway: Prime Therapeutics’ program will make the cancer care patient journey easier by connecting the care team to the practice pharmacy